Two-Drug combo aims to stop lung cancer recurrence after surgery
NCT ID NCT06055465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycles of the drug combination before surgery, followed by 13 cycles of pembrolizumab alone after surgery. The study focuses on patients with stage II–III NSCLC that is EGFR/ALK-negative and aims to see how many achieve a complete pathological response (no cancer cells in the removed tissue).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan and pembrolizumab
What this could lead to
If successful, this combination could lower the chance of lung cancer returning after surgery and improve survival for patients with resectable disease.
What could go wrong
This is an early phase 2 study with only 37 participants, so results may not apply to all patients. The drug combination may cause side effects like fatigue, nausea, or immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
-
Department of Clinical Oncology, Queen Elizabeth Hospital
Hong Kong, Hong Kong
-
Department of Clinical Oncology, Tuen Mun Hospital
Hong Kong, Hong Kong
-
Department of Oncology, Princess Margaret Hospital
Hong Kong, Hong Kong